

wherein  $R_1$  is selected from the group consisting of alkyl of 1 to 6 carbon atoms, alkenyl and alkynyl of 2 to 6 carbon atoms haloalkyl of 1 to 6 carbon atoms, alkoxy alkyl of 2 to 12 carbon atoms and alkylthioalkyl of 2 to 12 carbon atoms,  $R_p$  is hydrogen or an easily cleavable group,  $R_{18}$  and  $R_{19}$  are individually selected from the group consisting of hydrogen, halogen, OH and alkyl and alkoxy of 1 to 6 carbon atoms and its non-toxic, pharmaceutically acceptable salts.

REMARKS

Reconsideration of this application is requested in view of the amendments to the specification and claims and the remarks presented herein.

The claims in the application are claims 5 to 8 and 18 to 24, all other claims having been cancelled. Applicants are submitting herewith on a separate sheet of paper an Abstract of the Disclosure.

All of the claims were rejected under 35 USC 112, first paragraph, as being based upon a non-enabling disclosure for the breadth of the claims. The claims have been amended to the cancers that the Examiner deemed enabling and therefore, this ground of rejection is now moot.